Llwytho...

Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer

PURPOSE: HR+/HER2− aromatase inhibitor (AI)-resistant metastatic breast cancer can be treated with everolimus and a second AI until the cancer recurs. Targeting these everolimus-resistant patients with the latest standard of care, CDK4/6 inhibitors, has not been clearly addressed. Understanding the...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Breast Cancer Res Treat
Prif Awduron: Petrossian, Karineh, Nguyen, Duc, Lo, Chiao, Kanaya, Noriko, Somlo, George, Cui, Yvonne Xiaoyong, Huang, Chiun-Sheng, Chen, Shiuan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026053/
https://ncbi.nlm.nih.gov/pubmed/29623577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4779-x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!